Mode
Text Size
Log in / Sign up
N/A N=64 Randomized Quadruple-blind Treatment

Lubiprostone (Amitiza®) Vs. Standard Care in Opioid-induced Constipation After Surgery in Inpatient Rehabilitation

Constipation

Enrolled (actual)
64
Serious AEs
3.3%
Results posted
Feb 2013
Primary outcome: Primary: Change in Patient Assessment of Constipation (PAC) - Symptoms (Sym) — -0.22; -0.29 units on a scale — p=<0.05

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Lubiprostone (Drug); Senna (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Shirley Ryan AbilityLab
Primary completion
Oct 2011

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in Patient Assessment of Constipation (PAC) - Symptoms (Sym)
-0.22; -0.29 <0.05 sig
PRIMARY
Change in Patient Assessment of Constipation - Quality of Life
0.99; .42

Summary

Patients requiring opioids for post-operative pain control following elective orthopedic procedures which has resulted in constipation symptoms, and who are in inpatient rehabilitation will be randomized to two different treatment arms: lubiprostone or senna. Baseline scores regarding constipation and a quality of life bowel questionnaire will be compared the day following 6 days of treatment intervention.

Eligibility Criteria

Inclusion Criteria

  • Adult, 18 years old or greater.
  • The patient is able to provide informed consent.
  • Anticipated duration of hospitalization of at least 7 days.
  • Woman of childbearing potential must have a negative serum pregnancy test at enrollment. Exclusions for testing include two years or greater postmenopausal, hysterectomy or tubal ligation.
  • Use of opioid for post-op analgesia following orthopedic surgical procedures as defined as IV, IM, transdermal or PO opioid received within the prior 24 hours of hospitalization for pain control, and expectation that an opioid will be continued for pain control.
  • Medication may be administered on a PRN (as needed) basis or scheduled basis
  • One or greater doses has been received within the 24 hours prior to enrollment as determined by medication administration recorded from the acute care facility or RIC MAR.
  • At least one associated symptom of constipation at the time of admission, such as, but not limited to:
  • Lumpy or Hard stools
  • Feeling of incomplete evacuation of bowels
  • Abdominal cramping or pain
  • Straining with movement of bowels or painful bowel movement effort
  • Need for manual assistance to have a bowel movement

Exclusion Criteria

  • Known allergy or sensitivity to the study medications
  • Females who are pregnant
  • Diarrhea on the day of admission
  • Diagnosis of Clostridium difficile infection during the current hospitalization
  • Pre-existing medical condition or surgical procedure, which is known to commonly lead to bowel dysfunction such as, but not limited to:
  • Crohn's disease
  • Ulcerative colitis
  • Multiple sclerosis
  • Cerebral palsy
  • Spinal Cord Injury
  • Colectomy
  • Malabsorption Syndrome
  • Irritable Bowel Syndrome
  • Abdominopelvic neoplasm (gastric, colon cancer)
  • Severe liver disease
  • Colonic or ileo-colonic resections
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00662363). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search